ClinicalTrials.gg
CompletedNCT05714969Updated Jun 17, 2026

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

A Phase 2 interventional study of TAK-755 in Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda — 3 open to participants now, 4 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · Takeda.

Started
2023
the only one that year
Phase 2
2 of 10
none open now
Registered
6th of 10
by date

Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, this one is the only one that started in 2023, is one of 2 in phase 2, and was the 6th registered.

Purpura, Thrombotic Thrombocytopenic

67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.

Browse Purpura, Thrombotic Thrombocytopenic studies →

Open to participants now

3 of the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, or all of them as a file.
02

Study summary

This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response in Part 1 or platelet response in Part 2. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.

Read the detailed description

This study consists of 2-parts. Part 1 is a double-blind, randomized study in which participants were randomized 1:1, in a blinded fashion, into 2 TAK-755 dose groups. Part 1, randomization was stratified based on whether the participant had received pre-study PEX and on the participant's Glasgow Coma Scale. Part 2 is an open-label study in which participants with iTTP experiencing an acute iTTP episode will be enrolled and assigned to a single-arm treatment.

03

Conditions studied

  • Thrombotic Thrombocytopenic Purpura (TTP)

Keywords

  • Drug Therapy
  • Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria (Part 1 and Part 2)

  1. Participant must provide a signed form. A fully recognized proxy may be used per local laws for participants unable to provide consent.
  2. Participant is 18 years or older at time of screening.
  3. Participant has been diagnosed with de novo or iTTP.
  4. Participant must be willing to fully comply with study procedures and requirements.
  5. Female participants of must present with a negative pregnancy test and agree to employ highly effective measures for duration of study. Sexually active male participants must agree to use an effective method of contraception for the duration of the study.

Key Exclusion Criteria (Part 1 and Part 2)

  1. Participant has received more than 2 pre-study PEX prior to randomization in Part 1 or first dose of product in Part 2.
  2. Participant has been diagnosed with cTTP or another cause of thrombotic microangiopathy (TMA).
  3. Participant has been exposed to another investigational product within 30 days prior to enrollment or is scheduled to participate in another clinical study involving investigational product or investigational device during the course of the study.
  4. Participant has received caplacizumab within 30 days prior to study enrollment.
  5. Participant has had a previous iTTP event within the past 30 days.
  6. Participant is positive for (HIV) with unstable disease or cluster of differentiation (CD)4+ count ≤200 cells/mm\^3 within 3 months of screening.
  7. Participant has condition of severe immunodeficiency.
  8. Participant has a severe systemic acute infection.
  9. Participant has another underlying progressive fatal disease and/or \<3 months.
  10. Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.
  11. Participant is pregnant or lactating.
  12. Participant has any condition in which methylprednisolone or other equivalent is as per prescribing information.
  13. Participant has known life-threatening reaction, including anaphylaxis, to the parent molecule ADAMTS13, Chinese hamster ovary (CHO) cell proteins, or other constituents of TAK-755.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Part 1: TAK-755 Dose 1 in Acute Phase and Dose 2 in Post-acute Phase

    TAK-755 Dose 1, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.

    Biological: TAK-755

  • Experimental
    Part 1: TAK-755 Dose 2 in Both Acute and Post-Acute Phase

    TAK-755 Dose 2, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.

    Biological: TAK-755

  • Experimental
    Part 2: TAK-755 Dose 3 in Acute Phase and Dose 2 in Post-acute Phase

    TAK-755 Dose 3, IV infusion, in the acute phase until 48-hour platelet response is achieved. All participants achieving platelet response will receive TAK-755 at Dose 2, 4 times per week for Week 1 and 3 times per week for Week 2 and 3 during the post-acute phase based on investigator judgement as high-risk for developing iTTP recurrence.

    Biological: TAK-755

Interventions

  • BiologicalTAK-755

    TAK-755 IV infusion

    Also known as: rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESIs) After Receiving any Dose of Investigational Product (IP)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event. Adverse events of special interest include major thrombotic events and treatment-related bleeding events.

    Time frame: Through study completion, approximately 12 weeks

Secondary outcomes

  1. Part 1: Achievement of Clinical Response Without On-Study Plasma Exchange (PEX)

    Clinical response is defined as normalization of platelets and no clinical evidence of new or progressive ischemic organ injury. Normalization of platelets: First occurrence of normal platelet count (greater than or equal to \[\>=\]150,000/microliter \[mcL\]) that is followed by a confirmatory platelet count of \>=150,000/mcL and a lactate dehydrogenase (LDH) \<1.5×upper limit of normal (ULN) at 48±12 hours after the first occurrence.

    Time frame: Through study completion, approximately 12 weeks

  2. Part 2: Achievement of Platelet Response Without On-Study Plasma Exchange (PEX)

    Platelet response is defined as first occurrence of normal platelet count (\>=150,000/mcL) that is followed by a confirmatory platelet count of \>=150,000/mcL at 48±12 hours after the first occurrence.

    Time frame: Through study completion, approximately 12 weeks

  3. Part 1: Achievement of Clinical Response With Zero or Minimal on-Study PEX

    The number of PEX administered considered Zero when no PEX is administered and considered Minimal when 1 to 3 PEX are administered.

    Time frame: Through study completion, approximately 12 weeks

  4. Part 2: Achievement of Platelet Response With Zero or Minimal on-Study PEX

    The number of PEX administered considered Zero when no PEX is administered and considered Minimal when 1 to 3 PEX are administered.

    Time frame: Through study completion, approximately 12 weeks

  5. Part 1: Achievement of Clinical Response Overall

    Overall indicates clinical response regardless of whether on-study PEX is administered, or the number of PEX administered.

    Time frame: Through study completion, approximately 12 weeks

  6. Part 2: Achievement of Platelet Response Overall

    Overall indicates platelet response regardless of whether on-study PEX is administered, or the number of PEX administered.

    Time frame: Through study completion, approximately 12 weeks

  7. Part 1: Time to Clinical Response (Acute Phase)

    Time frame: Through study completion, approximately 12 weeks

  8. Part 2: Time to Platelet Response (Acute Phase)

    Time frame: Through study completion, approximately 12 weeks

  9. Part 1: Occurrence of Refractoriness (Acute Phase)

    Time frame: Through study completion, approximately 12 weeks

  10. Part 1: Time to First On-Study PEX in Participants who Achieved Clinical Response

    Time frame: Through study completion, approximately 12 weeks

  11. Part 2: Time to First On-Study PEX in Participants who Achieved Platelet Response

    Time frame: Through study completion, approximately 12 weeks

  12. Part 1: Number of Days of On-study PEX in Participants to Achieve Clinical Response (Acute Phase)

    Time frame: Through study completion, approximately 12 weeks

  13. Part 2: Number of Days of On-study PEX in Participants to Achieve Platelet Response (Acute Phase)

    Time frame: Through study completion, approximately 12 weeks

  14. Part 1: Total Volume of Plasma Administered (Acute Phase) to Achieve Clinical Response

    Time frame: Through study completion, approximately 12 weeks

  15. Part 2: Total Volume of Plasma Administered (Acute Phase) to Achieve Platelet Response

    Time frame: Through study completion, approximately 12 weeks

  16. Part 1: Occurrence of Treatment Failure

    Treatment failure is defined as failure to achieve clinical response, or experience iTTP recurrence.

    Time frame: Through study completion, approximately 12 weeks

  17. Part 2: Occurrence of Treatment Failure

    Treatment failure is defined as failure to achieve platelet response, or experience iTTP recurrence.

    Time frame: Through study completion, approximately 12 weeks

  18. Part 1: Occurrence of Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) Recurrence (Following Clinical Response), Exacerbation, or Relapse (Post-acute Phase)

    iTTP recurrence comprised of exacerbation or relapse. Clinical exacerbation: Occurs \<30 days after achieving initial clinical response (i.e., before clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy. Clinical relapses: Occurs \>=30 days after achieving initial clinical response (i.e., after clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy.

    Time frame: Through study completion, approximately 12 weeks

  19. Part 2: Occurrence of iTTP Recurrence (Following Platelet Response), Exacerbation, or Relapse (Post-acute Phase)

    iTTP recurrence comprised of exacerbation or relapse. Clinical exacerbation: Occurs \<30 days after achieving initial platelet response (i.e., before clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy. Clinical relapses: Occurs \>=30 days after achieving initial platelet response (i.e., after clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy.

    Time frame: Through study completion, approximately 12 weeks

  20. Part 1: Time to iTTP Recurrence (Following Clinical Response), Exacerbation, or Relapse

    Time frame: Through study completion, approximately 12 weeks

  21. Part 2: Time to iTTP Recurrence (Following Platelet Response), Exacerbation, or Relapse

    Time frame: Through study completion, approximately 12 weeks

  22. Part 1: Occurrence of Any One of the Following Events: Clinical Recurrence (Following Clinical Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion

    Time frame: Through study completion, approximately 12 weeks

  23. Part 2: Occurrence of Any One of the Following Events: Clinical Recurrence (Following Platelet Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion

    Time frame: Through study completion, approximately 12 weeks

  24. Part 1: Time to Occurrence of Any One of the Following Events: Clinical Recurrence (Following Clinical Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion

    Time frame: Through study completion, approximately 12 weeks

  25. Part 2: Time to Occurrence of Any One of the Following Events: Clinical Recurrence (Following Platelet Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion

    Time frame: Through study completion, approximately 12 weeks

  26. Part 1: Change From Baseline in Lactate Dehydrogenase [LDH] Levels at Clinical Response and Study Completion

    Time frame: Through study completion, approximately 12 weeks

  27. Part 2: Change From Baseline in LDH Levels at Platelet Response and Study Completion

    Time frame: Through study completion, approximately 12 weeks

  28. Part 1: Change From Baseline in Troponin Levels at Clinical Response and Study Completion

    Time frame: Through study completion, approximately 12 weeks

  29. Part 2: Change From Baseline in Troponin Levels at Platelet Response and Study Completion

    Time frame: Through study completion, approximately 12 weeks

  30. Part 1: Achievement of Clinical Remission

    Clinical remission is defined as achieving clinical response and no recurrence for \>=30 days.

    Time frame: Through study completion, approximately 12 weeks

  31. Part 2: Achievement of Clinical Remission

    Clinical remission is defined as achieving platelet response and no recurrence for \>=30 days.

    Time frame: Through study completion, approximately 12 weeks

  32. Part 1 and 2: A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) Antigen Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases

    Time frame: Through study completion, approximately 12 weeks

  33. Part 1 and 2: ADAMTS13 Activity Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases

    Time frame: Through study completion, approximately 12 weeks

  34. Part 1: Von Willebrand Factor (VWF) Antigen Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases

    Time frame: Through study completion, approximately 12 weeks

  35. Part 1: VWF Activity Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases

    Time frame: Through study completion, approximately 12 weeks

07

Study locations

22 sites
  • University of Florida - Shands
    Gainesville, Florida 32610, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Minnesota Clinical Research Unit
    Minneapolis, Minnesota 55455, United States
  • Rutgers University
    New Brunswick, New Jersey 08901, United States
  • Weill Cornell
    New York, New York 10021, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Leo Jenkins Cancer Center/ECU School of Medicine
    Greenville, North Carolina 27858, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • Versiti Wisconsin, Inc.
    Milwaukee, Wisconsin 53226, United States
  • AKH - Medizinische Universitat Wien
    Vienna, 1090, Austria
  • General Hospital of Thessaloniki "G. Papanikolaou"
    Thessaloniki, 57010, Greece
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Hospital Universitario Virgen del Rocio
    Seville, Sevilla 41010, Spain
  • Hospital de Cruces
    Barakaldo, Vizcaya 48903, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • University College London Hospital
    London, Greater London NW1 2PG, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, Merseyside L7 8XP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: NOTE: IPD Sharing Time Frame has not been entered.

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Apr 2026, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2023
First posted
Feb 6, 2023
StartActual
Jul 21, 2023
Primary completionActual
Apr 16, 2026
CompletionActual
Apr 16, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05714969
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Jul 21, 2023
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026
Last update
Jun 17, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apadamtase alfa

Start the discussion